Matches in SemOpenAlex for { <https://semopenalex.org/work/W3172912181> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- W3172912181 abstract "Neratinib (NERLYNX®) is a pan-HER tyrosine kinase inhibitor newly approved by FDA in 2017 and post to European market in 2018 to treat HER2-positive breast cancer, but the approval of neratinib has been controversial. Previous retrospective analysis showed that neratinib did not harm patients' quality of life, while another cost-benefit analysis indicated that neratinib's severe side effect comprises its cost-effectiveness. The phase III trial of neratinib showed that 96% of the patients taking neratinib experienced diarrhea. However, very few mechanistic studies have done to explore neratinib-induced gastrointestinal (GI) toxicity. Hereby, we performed toxicity studies in mice to characterize the potential mechanism underlying this adverse effect. C57BL/6 J (female, 5-weeks old) mice were randomly separated into three groups A, B, C. Group A received vehicle; group B was orally dosed with 100mg/kg neratinib once daily for 18 days. Group C was dosed with 100mg/kg neratinib for 12 days and switched to vehicle later for 6 days. Intestine and liver were collected for further analysis. Caco2, HT29 and Colo320DM cells were treated with neratinib in vitro. Our results showed that 12 days treatment of neratinib caused persistent histological damage in mouse GI tract, including blunted villi in small intestine and inflammatory infiltrate in colon. The gene expression of Cyp3a11, the major enzyme metabolizing neratinib in mice was significantly reduced in small intestine. The gene expression of proinflammatory cytokines, TNF-α, IL-6 and IL-1β, increased throughout the GI tract. Such damages were not recovered after 6 days without neratinib treatment. In addition, in vitro data showed that neratinib was potent in killing human intestine derived cell lines but did not reduce CYP3A4 expression in those cells. Based on such findings, we concluded that neratinib triggered inflammatory response in gut. And the release of cytokines downregulated intestinal CYP3A. With lower level of CYP3A, there is likely neratinib accumulation. It eventually leads to high risk of diarrhea. Our findings give new insight into the mechanism of neratinib-induced GI toxicity." @default.
- W3172912181 created "2021-06-22" @default.
- W3172912181 creator A5030684803 @default.
- W3172912181 creator A5080819129 @default.
- W3172912181 date "2021-05-01" @default.
- W3172912181 modified "2023-09-25" @default.
- W3172912181 title "Neratinib reduces CytochromP450 3A enzymes in mouse intestine" @default.
- W3172912181 doi "https://doi.org/10.1096/fasebj.2021.35.s1.05264" @default.
- W3172912181 hasPublicationYear "2021" @default.
- W3172912181 type Work @default.
- W3172912181 sameAs 3172912181 @default.
- W3172912181 citedByCount "0" @default.
- W3172912181 crossrefType "journal-article" @default.
- W3172912181 hasAuthorship W3172912181A5030684803 @default.
- W3172912181 hasAuthorship W3172912181A5080819129 @default.
- W3172912181 hasConcept C121608353 @default.
- W3172912181 hasConcept C126322002 @default.
- W3172912181 hasConcept C143998085 @default.
- W3172912181 hasConcept C2779413316 @default.
- W3172912181 hasConcept C2779786085 @default.
- W3172912181 hasConcept C2779802037 @default.
- W3172912181 hasConcept C530470458 @default.
- W3172912181 hasConcept C71924100 @default.
- W3172912181 hasConcept C90924648 @default.
- W3172912181 hasConceptScore W3172912181C121608353 @default.
- W3172912181 hasConceptScore W3172912181C126322002 @default.
- W3172912181 hasConceptScore W3172912181C143998085 @default.
- W3172912181 hasConceptScore W3172912181C2779413316 @default.
- W3172912181 hasConceptScore W3172912181C2779786085 @default.
- W3172912181 hasConceptScore W3172912181C2779802037 @default.
- W3172912181 hasConceptScore W3172912181C530470458 @default.
- W3172912181 hasConceptScore W3172912181C71924100 @default.
- W3172912181 hasConceptScore W3172912181C90924648 @default.
- W3172912181 hasIssue "S1" @default.
- W3172912181 hasLocation W31729121811 @default.
- W3172912181 hasOpenAccess W3172912181 @default.
- W3172912181 hasPrimaryLocation W31729121811 @default.
- W3172912181 hasRelatedWork W1506813245 @default.
- W3172912181 hasRelatedWork W2021331582 @default.
- W3172912181 hasRelatedWork W2372469506 @default.
- W3172912181 hasRelatedWork W2407640552 @default.
- W3172912181 hasRelatedWork W2411360264 @default.
- W3172912181 hasRelatedWork W2417633704 @default.
- W3172912181 hasRelatedWork W2474169020 @default.
- W3172912181 hasRelatedWork W4254029160 @default.
- W3172912181 hasRelatedWork W93022519 @default.
- W3172912181 hasRelatedWork W2097910047 @default.
- W3172912181 hasVolume "35" @default.
- W3172912181 isParatext "false" @default.
- W3172912181 isRetracted "false" @default.
- W3172912181 magId "3172912181" @default.
- W3172912181 workType "article" @default.